#POLB Poolbeg Pharma PLC – Annual Report & AGM Notice
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, confirms that the Company’s Annual Report and Accounts for the period ended 31 December 2022 and the notice of Annual General Meeting (“AGM”) 2022 have been posted to shareholders. The 2022 […]
#POLB Poolbeg Pharma – Key POLB 002 European Patent Granted
– Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, provides an update on the strengthening of its intellectual property (IP) for its asset POLB 002, a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections. In January this […]
Poolbeg Pharma #POLB – POLB 001 Clinical Development – Clinical Trial Agreement Signed
31 March, 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’) announces that it has signed a Clinical Trial Agreement with the Centre for Human Drug Research (CHDR) in the Netherlands for the completion of a bacterial lipopolysaccharide (‘LPS’) human challenge study of POLB 001, which is due to commence in June […]
Poolbeg Pharma #POLB – Licenses RNA-based immunotherapy asset
Broadcast Event Detail
Open Orphan #ORPH – Positive Phase 1 study results published in The Lancet
Monday 15th June, 2020 Positive results from the Phase I study of the AGS-v vaccine developed by an Open Orphan joint venture, Imutex Limited, have been published in the peer reviewed journal The Lancet AGS-v is a first-in-class mosquito saliva, standalone, vaccine candidate designed to protect against mosquito-borne diseases carried in the saliva such as Zika, Malaria, […]
Experts seek approval for COVID-19 trials – China Daily
By ANGUS McNEICE in London Medical community divided on issue of exposing humans to deadly virus A laboratory in the United Kingdom is hoping to become the first in the world to intentionally infect volunteers with novel coronavirus in order to test the efficacy of COVID-19 vaccines. Half of the participants in these so-called human […]